Research Paper Volume 15, Issue 15 pp 7476—7495
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
Figure 1. The detailed work process of this study. SETBP1 mutations were determined as a potential biomarker for melanoma and NSCLC clinical ICI treatments.